Brachytherapy for Prostate Cancer 2017

Summary of first presentation

 Long-term morbidity rate is low. (LoE: III)

 Technical advances improve tumor control and lower toxicity.

 Careful patient selection is important to avoid unacceptable morbidity.

 Urgent need for prospective trials to investigate on medical approaches to the treatment of morbidity.